Investment analysts at Chardan Capital issued their FY2026 EPS estimates for Krystal Biotech in a research note issued to ...

Krystal Biotech, Inc. (KRYS) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings ...

Krystal Biotech's VYJUVEK sees strong growth with $1B+ 2025 sales forecast. Check out why I rate KRYS as a Strong Buy and my ...

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Get Free Report) have been given an average recommendation of “Buy” by the ...

Citi analyst Yigal Nochomovitz raised the firm’s price target on Krystal Biotech (KRYS) to $215 from $206 and keeps a Neutral rating on the ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $217.33, a high estimate of $221.00, and a low estimate of $212.00. Surpassing the previous average price ...

Krystal Biotech is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK is ...

South Side-based biotechnology firm Krystal Biotech Inc.'s stock is up 20% following its earnings call this morning.

Thank you for standing by and welcome to the Krystal Biotech Q4 2024 earnings call. (Operator Instructions) As a reminder, today's conference is being recorded. I would now like to hand the conference ...

周四，在Krystal Biotech（纳斯达克代码：KRYS）于2月19日公布2024年财务业绩后，H.C.